Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients

Biomedicine and Pharmacotherapy

Volumn 50, Issue 8, 1996, Pages 344-349

  Nicolini, A ^a,b   Mancini, P A ^a   Ferrari, P ^a   Anselmi, L ^a   Sagripanti, A ^a   Carpi, A ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Breast and colorectal cancer; Conventional salvage therapy; rIL 2

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; B LYMPHOCYTE; BREAST CANCER; CLINICAL ARTICLE; COLORECTAL CANCER; CONFERENCE PAPER; DRUG TOLERANCE; EOSINOPHIL; HUMAN; IMMUNE SYSTEM; INFLUENZA; LIVER FUNCTION TEST; LIVER TOXICITY; NATURAL KILLER CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

EID: 0029853118     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(96)89666-1     Document Type: Conference Paper

References (18)

1. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon alpha-2b in advanced human malignancies. Lancet 1968;335:1509-12
2. Broom J, Heys SD, Whiting PH et al. Interleukin-2 therapy in cancer: identification of responders. Br J Cancer 1992;66:1185-7
3. Caligiuri MA. Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Semin Oncol 1993;20(suppl 9):3-10
4. Gautam SC, Chikkala NF, Ganapathi R, Hamilton TA. Combination therapy with adriamycin and interleukin-2 augments immunity against murine renal cell carcinoma. Cancer Res 1991;51:6133-7
5. Hamblin TJ, Williamson PJ, George DK, Oskam R, Palmer PA, Franks CR. A phase II study of human rIL-2 and 5-FU chemotherapy in the treatment of metastatic colorectal carcinoma. Am Soc Clin Oncol 1990;9:433
6. Lee KH, Talpaz M, Rothberg JM et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2a in cancer patients: a phase I study. J Clin Oncol 1989;7:1726-32
7. Lissoni P, Barni S, Ardizzoia A et al. Second-line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer 1992;28:92-6
8. Lopez A, Di Lauro L, Gionfra T, Gandolfo G, Ameglio F, Paoletti G. Thymopentin and interleukin-2 in combination with 5-fluorouracil and leucovorin in metastatic colorectal adenocarcinoma: preliminary results. J Surg Oncol 1991; suppl 2:108-11
9. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. J Am Med Assoc 1986;256 (22):3117-24
10. Maas RA, Dullens HFJ, Otter WD. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother 1993;36:141-8
11. Negrier S, Philip T, Stoter G et al. Interleukin-2 with or without LAK cells in metastatic renal cancer cell carcinoma: a report of a European Multicentre Study. Eur J Cancer 2989;25(suppl 3):S21-28
12. Nicolini A, Colombini C, Luciani L, Carpi A, Giuliani L. Evaluation of serum Ca15.3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 1991;64:154-8
13. Nicolini A, Caciagli M, Zampieri F. Usefulness of CEA, TPA, GICA, Ca 72.4 and Ca 195 in the diagnosis of primary colorectal cancer and at its relapse. Cancer Det Prev 1995;19:183-95
14. Paciucci PA, Holland JF, Ryder JS et al. Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin. Cancer Treat Rev 1989;16:67-81
15. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous limphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313 (23):1485-92
16. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316 (15):889-97
17. Stein RC, Malkovska V, Morgan S et al. The clinical effects of prolonged treatment of patients with advanced cancer with low- dose subcutaneous interleukin-2. Br J Cancer 1991;63:275-8
18. West WH, Tauer KW, Yannelli JR et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905